CN118086404A - 重组慢病毒Lenti-shRRP15的制备和特异性应用杀伤神经胶质瘤细胞 - Google Patents
重组慢病毒Lenti-shRRP15的制备和特异性应用杀伤神经胶质瘤细胞 Download PDFInfo
- Publication number
- CN118086404A CN118086404A CN202410117883.8A CN202410117883A CN118086404A CN 118086404 A CN118086404 A CN 118086404A CN 202410117883 A CN202410117883 A CN 202410117883A CN 118086404 A CN118086404 A CN 118086404A
- Authority
- CN
- China
- Prior art keywords
- shrrp
- cells
- cell culture
- recombinant lentivirus
- lenti
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010018338 Glioma Diseases 0.000 title claims abstract description 31
- 208000032612 Glial tumor Diseases 0.000 title claims abstract description 29
- 241000713666 Lentivirus Species 0.000 title claims abstract description 28
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 239000013612 plasmid Substances 0.000 claims abstract description 23
- 238000004113 cell culture Methods 0.000 claims abstract description 16
- 108020004459 Small interfering RNA Proteins 0.000 claims abstract description 11
- 241000700605 Viruses Species 0.000 claims abstract description 9
- 238000001890 transfection Methods 0.000 claims abstract description 9
- 239000012228 culture supernatant Substances 0.000 claims abstract description 8
- 239000011543 agarose gel Substances 0.000 claims abstract description 4
- 238000000137 annealing Methods 0.000 claims abstract description 4
- 238000010367 cloning Methods 0.000 claims abstract description 4
- 239000012141 concentrate Substances 0.000 claims abstract description 4
- 238000002156 mixing Methods 0.000 claims abstract description 4
- 101150082104 RRP15 gene Proteins 0.000 claims description 7
- 238000005119 centrifugation Methods 0.000 claims description 3
- 101000683518 Homo sapiens RRP15-like protein Proteins 0.000 abstract description 15
- 102100023534 RRP15-like protein Human genes 0.000 abstract description 15
- 102100021010 Nucleolin Human genes 0.000 abstract description 4
- 230000000694 effects Effects 0.000 abstract description 4
- 108010044762 nucleolin Proteins 0.000 abstract description 4
- 230000000259 anti-tumor effect Effects 0.000 abstract description 3
- 238000012258 culturing Methods 0.000 abstract description 3
- 238000003786 synthesis reaction Methods 0.000 abstract description 3
- 238000012408 PCR amplification Methods 0.000 abstract 1
- 238000011084 recovery Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 37
- 230000014509 gene expression Effects 0.000 description 11
- 238000002560 therapeutic procedure Methods 0.000 description 9
- 238000012545 processing Methods 0.000 description 7
- 108020004418 ribosomal RNA Proteins 0.000 description 7
- 241000699660 Mus musculus Species 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 238000011580 nude mouse model Methods 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000000243 solution Substances 0.000 description 4
- 101100517196 Arabidopsis thaliana NRPE1 gene Proteins 0.000 description 3
- 101100190825 Bos taurus PMEL gene Proteins 0.000 description 3
- 101100073341 Oryza sativa subsp. japonica KAO gene Proteins 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 101150005492 rpe1 gene Proteins 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 210000003705 ribosome Anatomy 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 102000000412 Annexin Human genes 0.000 description 1
- 108050008874 Annexin Proteins 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000003197 gene knockdown Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
本发明涉及重组慢病毒Lenti‑shRRP15的制备和特异性应用杀伤神经胶质瘤细胞。以一种siRNA序列为靶点的shRRP15引物进行化学合成,将引物等比例混和退火后,得到shRRP15序列,使用引物对慢病毒质粒pLKO.1进行PCR扩增,并进行琼脂糖凝胶回收,使用无缝克隆试剂盒连接shRRP15和质粒pLKO.1,得到慢病毒载体质粒pLKO‑shRRP15,应用细胞转染试剂盒SuperFect转染慢病毒质粒pLKO‑shRRP15和辅助载体质粒共转染293T细胞,细胞转染12小时后,更换细胞培养液;细胞培养24小时后,收集细胞培养上清,细胞继续培养24小时,再次收集细胞培养上清,离心收集病毒浓缩液,得到重组慢病毒Lenti‑shRRP15,利用慢病毒作为载体感染神经胶质瘤细胞,以核仁蛋白分子RRP15作为特异性抗肿瘤治疗的靶标,制备慢病毒Lenti‑shRRP15制剂进行神经胶质瘤治疗,具有高效、高特异、低副作用等巨大优势。
Description
技术领域
本发明涉及生物医药技术领域,尤其涉及重组慢病毒Lenti-shRRP15的制备和特异性应用杀伤神经胶质瘤细胞。
背景技术
核糖体RNA加工蛋白RRP15是一种参与核糖体RNA加工的蛋白质,核糖体RNA加工是指在核糖体合成过程中,对核糖体RNA进行修饰和加工的过程,RRP15在这一过程中起到了重要的作用,它参与了核糖体RNA的修饰和加工,确保核糖体的正常合成和功能,核仁蛋白RRP15对核糖体大亚基的成熟至关重要,抑制细胞内RRP15的表达,导致肿瘤细胞死亡,而正常细胞仅发生周期阻滞,间歇性抑制细胞内RRP15基因表达,最终导致所有肿瘤细胞死亡,相反不影响正常细胞的生长,因此,核仁蛋白RRP15可以作为特异性抗肿瘤治疗的靶标;
目前尚不清楚核糖体RNA加工蛋白RRP15与神经胶质瘤之间是否存在直接的关联,然而,生物信息学研究显示RRP15在神经胶质瘤发生和发展中可能起到重要的作用,RRP15蛋白的异常表达与神经胶质瘤的发生和预后密切相关,因此,进一步研究核糖体RNA加工蛋白RRP15与神经胶质瘤之间的关系可能有助于我们更好地理解神经胶质瘤的发生机制,并为其治疗提供新的靶点;
慢病毒治疗是一种基因治疗方法,可以用于治疗神经胶质瘤,神经胶质瘤是一种恶性肿瘤,通常难以完全切除,并且对传统的放疗和化疗方法反应有限,慢病毒治疗利用慢病毒作为载体,将特定的基因导入肿瘤细胞中,以达到治疗的目的,这些基因可以通过不同的机制来抑制肿瘤细胞的生长和扩散,或者增强免疫系统对肿瘤的攻击能力,慢病毒治疗的优势在于它可以通过基因导入来实现针对性治疗,避免了传统治疗方法对正常细胞的损伤,此外,慢病毒治疗还可以通过改变肿瘤细胞的基因表达,使其对传统治疗方法更敏感,然而,慢病毒治疗也存在一些挑战和风险,首先,慢病毒治疗需要有效地将基因导入肿瘤细胞中,这可能受到肿瘤组织的限制和免疫系统的排斥,其次,慢病毒治疗可能引起免疫反应,导致治疗效果不佳或不可预测的副作用,总的来说,慢病毒治疗是一种有潜力的治疗神经胶质瘤的方法,但仍需要进一步的实验室基础研究和临床实践来验证其安全性和有效性。
发明内容
为达到上述目的,本发明采用如下技术方案:
重组慢病毒Lenti-shRRP15的制备,其特征在于一种靶向RRP15基因的siRNA序列为5’-CCAGAATCTGCAAGTGACTCTGATA-3’(844—869碱基);重组慢病毒Lenti-shRRP15的制备步骤为:
1)设计以上述siRNA序列为靶点的shRRP15引物,并进行化学合成:
引物1:5’
-GATAGAGACACCGGTGTGCCAGAATCTGCAAGTGACTCTCTCGAGAGAGTCACTTGCAGATTCTGGTTTTTGTAGAATTCTC-3’;
引物2:5’
-GAGAATTCTACAAAAATCTCAGTGAACGTCTAAGACCCTCGAGGGTCTTAGACGTTCACTGAGACACACCGGTGTCTCTATC-3’;
2)将上述2个引物等比例混和退火后,得到shRRP15序列;
3)使用下述引物对慢病毒质粒pLKO.1进行PCR扩增,并进行琼脂糖凝胶回收;
引物1:5’-TTTTTGTAGAATTCTC-3’;
引物2:5’-CACACCGGTGTCTCTATC-3’;
4)使用无缝克隆试剂盒连接shRRP15和质粒pLKO.1,得到慢病毒载体质粒pLKO-shRRP15;
5)应用细胞转染试剂盒SuperFect转染慢病毒质粒pLKO-shRRP15和辅助载体质粒(pMD2.G和psPAX2)共转染293T细胞(各质粒质量比3:2:2);细胞转染12小时后,更换细胞培养液;
6)细胞培养24小时后,收集细胞培养上清;
7)细胞继续培养24小时,再次收集细胞培养上清,离心收集病毒浓缩液,得到重组慢病毒Lenti-shRRP15。
2.所述重组慢病毒Lenti-shRRP15在杀伤神经胶质瘤细胞的特异性应用。本发明的有益效果:
本发明利用慢病毒(lentivirus)作为载体感染神经胶质瘤细胞,以核仁蛋白分子RRP15作为特异性抗肿瘤治疗的靶标,制备慢病毒Lenti-shRRP15制剂进行神经胶质瘤治疗,具有高效、高特异、低副作用等巨大优势。
附图说明
图1为本发明设计高效抑制RRP15基因表达的siRNA序列示意图;
图2为本发明重组慢病毒Lenti-shRRP15抑制神经胶质瘤细胞U87MG和正常细胞RPE1内RRP15蛋白的表达的示意图;
图3为本发明重组慢病毒Lenti-shRRP15对神经胶质瘤细胞的特异性杀伤作用示意图;
图4为本发明重组慢病毒Lenti-shRRP15抑制神经胶质瘤在裸鼠体内生长每周记录裸鼠内肿瘤体积大小记录图;
图5为本发明重组慢病毒Lenti-shRRP15抑制神经胶质瘤在裸鼠体内生长中肿瘤组织的体积、重量检测图;
具体实施方式
下面将结合附图对本发明的技术方案进行清楚、完整地描述,显然,所描述的实施例是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
在本发明的描述中,需要说明的是,术语“中心”、“上”、“下”、“左”、“右”、“竖直”、“水平”、“内”、“外”等指示的方位或位置关系为基于附图所示的方位或位置关系,仅是为了便于描述本发明和简化描述,而不是指示或暗示所指的装置或元件必须具有特定的方位、以特定的方位构造和操作,因此不能理解为对本发明的限制。此外,术语“第一”、“第二”、“第三”仅用于描述目的,而不能理解为指示或暗示相对重要性。
在本发明的描述中,需要说明的是,除非另有明确的规定和限定,术语“安装”、“相连”、“连接”应做广义理解,例如,可以是固定连接,也可以是可拆卸连接,或一体地连接;可以是机械连接,也可以是电连接;可以是直接相连,也可以通过中间媒介间接相连,可以是两个元件内部的连通。对于本领域的普通技术人员而言,可以具体情况理解上述术语在本发明中的具体含义。此外,下面所描述的本发明不同实施方式中所涉及的技术特征只要彼此之间未构成冲突就可以相互结合。
实施例1
1.设计高效抑制RRP15基因表达的siRNA序列
1)使用BLOCK-iTTMRNAi Designer软件,搜索靶向RRP15基因的siRNA序列,并筛选最高分值靶向序列。选取前3个序列,设计siRNA并进行合成;
I 5’-CCAAACAGACTGAAGTGAAATCAGA-3’(722—747碱基)
II 5’-CAAACAGACTGAAGTGAAATCAGAA-3’(723—748碱基)
III 5’-CCAGAATCTGCAAGTGACTCTGATA-3’(844—869碱基)
2)使用细胞转染试剂Lipo8000,分别转染上述3个siRNA至神经胶质瘤细胞株U87MG;
3)结果显示,III号siRNA抑制RRP15基因表达效果最佳。后续选择以III号序列为靶点构建敲降RRP15表达的慢病毒。
2.重组慢病毒Lenti-shRRP15的制备
1)设计以上述III号序列为靶点的shRRP15引物,并进行化学合成:
引物1:5’
-GATAGAGACACCGGTGTGCCAGAATCTGCAAGTGACTCTCTCGAGAGAGTCACTTGCAGATTCTGGTTTTTGTAGAATTCTC-3’;
引物2:5’
-GAGAATTCTACAAAAATCTCAGTGAACGTCTAAGACCCTCGAGGGTCTTAGACGTTCACTGAGACACACCGGTGTCTCTATC-3’;
2)将上述2个引物等比例混和退火后,得到shRRP15序列;
3)使用下述引物对慢病毒质粒pLKO.1进行PCR扩增,并进行琼脂糖凝胶回收;
引物1:5’-TTTTTGTAGAATTCTC-3’;
引物2:5’-CACACCGGTGTCTCTATC-3’;
4)使用无缝克隆试剂盒连接shRRP15和质粒pLKO.1,得到慢病毒载体质粒pLKO-shRRP15;
5)应用细胞转染试剂盒SuperFect转染慢病毒质粒pLKO-shRRP15和辅助载体质粒(pMD2.G和psPAX2)共转染293T细胞(各质粒质量比3:2:2);细胞转染12小时后,更换细胞培养液;
6)细胞培养24小时后,收集细胞培养上清;
7)细胞继续培养24小时,再次收集细胞培养上清,离心收集病毒浓缩液,得到重组慢病毒Lenti-shRRP15。
3.重组慢病毒Lenti-shRRP15抑制神经胶质瘤细胞U87MG和正常细胞RPE1内RRP15蛋白的表达
1)体外培养神经胶质瘤细胞U87MG和正常二倍体非转化细胞RPE1;
2)以1:100比例稀释病毒液加入上述细胞,培养2天;
3)收集细胞,裂解后进行蛋白电泳,转膜后应用特异性面抗RRP15抗体进行Western Blot。
结果显示RRP15蛋白在细胞内的表达发生抑制。
4.重组慢病毒Lenti-shRRP15对神经胶质瘤细胞的特异性杀伤作用
1)以1:100比例稀释病毒液分别神经胶质瘤细胞U87MG和正常细胞RPE1;
2)3天后,收集细胞,进行70%乙醇固定,ANNEXIN V-PI共染色后应用流式细胞仪检测分析细胞凋亡情况。
结果显示,重组慢病毒Lenti-shRRP15感染导致神经胶质瘤细胞发生凋亡,相反正常细胞没有明显死亡。
5.重组慢病毒Lenti-shRRP15抑制神经胶质瘤在裸鼠体内生长
1)收集1×106神经胶质瘤细胞,植入裸鼠腋窝皮下;
2)2周后,在神经胶质瘤细胞成瘤部位注射Lenti-shRRP15病毒液(以正常生理盐水作为对照);
3)继续饲养小鼠2周,每周记录裸鼠内肿瘤体积大小;
4)处死小鼠,取出肿瘤组织,进行体积、重量检测。
结果显示,重组慢病毒Lenti-shRRP15显著抑制神经胶质瘤的生长。
以上显示和描述了本发明的基本原理和主要特征和本发明的优点。本发明提到的各个部件为现有领域常见技术,本行业的技术人员应该了解,本发明不受上述实施例的限制,上述实施例和说明书中描述的只是说明本发明的原理,在不脱离本发明精神和范围的前提下,本发明还会有各种变化和改进,这些变化和改进都落入要求保护的本发明范围内。本发明要求保护范围由所附的权利要求书及其等效物界定。
Claims (2)
1.重组慢病毒Lenti-shRRP15的制备,其特征在于一种靶向RRP15基因的siRNA序列为5’-CCAGAATCTGCAAGTGACTCTGATA-3’(844—869碱基);重组慢病毒Lenti-shRRP15的制备步骤为:
1)设计以上述siRNA序列为靶点的shRRP15引物,并进行化学合成:
引物1:5’
-GATAGAGACACCGGTGTGCCAGAATCTGCAAGTGACTCTCTCGAGAGAGTCACTTGCAGATTCTGGTTTTTGTAGAATTCTC-3’;
引物2:5’
-GAGAATTCTACAAAAATCTCAGTGAACGTCTAAGACCCTCGAGGGTCTTAGACGTTCACTGAGACACACCGGTGTCTCTATC-3’;
2)将上述2个引物等比例混和退火后,得到shRRP15序列;
3)使用下述引物对慢病毒质粒pLKO.1进行PCR扩增,并进行琼脂糖凝胶回收;引物1:5’-TTTTTGTAGAATTCTC-3’;
引物2:5’-CACACCGGTGTCTCTATC-3’;
4)使用无缝克隆试剂盒连接shRRP15和质粒pLKO.1,得到慢病毒载体质粒pLKO-shRRP15;
5)应用细胞转染试剂盒SuperFect转染慢病毒质粒pLKO-shRRP15和辅助载体质粒(pMD2.G和psPAX2)共转染293T细胞(各质粒质量比3:2:2);细胞转染12小时后,更换细胞培养液;
6)细胞培养24小时后,收集细胞培养上清;
7)细胞继续培养24小时,再次收集细胞培养上清,离心收集病毒浓缩液,得到重组慢病毒Lenti-shRRP15。
2.根据权利要求1中所述的重组慢病毒Lenti-shRRP15在杀伤神经胶质瘤细胞的特异性应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202410117883.8A CN118086404A (zh) | 2024-01-29 | 2024-01-29 | 重组慢病毒Lenti-shRRP15的制备和特异性应用杀伤神经胶质瘤细胞 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202410117883.8A CN118086404A (zh) | 2024-01-29 | 2024-01-29 | 重组慢病毒Lenti-shRRP15的制备和特异性应用杀伤神经胶质瘤细胞 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN118086404A true CN118086404A (zh) | 2024-05-28 |
Family
ID=91160620
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202410117883.8A Pending CN118086404A (zh) | 2024-01-29 | 2024-01-29 | 重组慢病毒Lenti-shRRP15的制备和特异性应用杀伤神经胶质瘤细胞 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN118086404A (zh) |
-
2024
- 2024-01-29 CN CN202410117883.8A patent/CN118086404A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107723275B (zh) | 通用型car-t细胞及其制备方法和应用 | |
CN105886534A (zh) | 一种抑制肿瘤转移的方法 | |
CN108753726B (zh) | 一种含有ECRG4 mRNA的外泌体及其制备方法和应用 | |
CN107541513B (zh) | 用于沉默cd317的小分子干扰rna、重组载体、药物及其应用 | |
CN101319215A (zh) | 人肿瘤特异性Ki67基因启动子 | |
CN110358735B (zh) | 一种ctl细胞的制备方法及应用 | |
CN113416768A (zh) | Prkra基因作为靶点在抑制小反刍兽疫病毒复制中的应用 | |
CN118086404A (zh) | 重组慢病毒Lenti-shRRP15的制备和特异性应用杀伤神经胶质瘤细胞 | |
CN113528528B (zh) | 一种促进耐伊马替尼慢性髓细胞白血病细胞K562/G01凋亡shRNA及其应用 | |
CN112980888B (zh) | 分泌il-6抗体/cd20抗体的间充质干细胞、构建方法及其应用 | |
CN108866099A (zh) | 特异性抑制肺腺癌细胞miRNA-21-5p表达的重组慢病毒载体及其构建方法 | |
CN108949827B (zh) | 特异抑制肺癌PPARd基因表达的shRNA慢病毒表达载体及其构建方法与应用 | |
CN109112129B (zh) | 用于靶向敲除人OC-2基因的特异性sgRNA及应用 | |
WO2021037232A1 (zh) | 编辑造血干/祖细胞中bcl11a基因的方法 | |
CN114213505A (zh) | 一种适用于特异感染u87-mg细胞的腺相关病毒突变体 | |
CN107190007B (zh) | 一种特异性敲减人brcc3基因慢病毒的构建及在肺癌中的应用 | |
WO2022052909A1 (zh) | 编辑造血干/祖细胞中bcl11a基因的方法 | |
CN115813945B (zh) | Dhrsx抑制剂在制备脑胶质瘤药物中的应用 | |
CN111575287B (zh) | 一种抑制NK细胞KIR 2DL3受体表达的siRNA及其应用 | |
CN114075548B (zh) | 一种靶向axl的car-t细胞及其制备方法和应用 | |
CN113846166B (zh) | 用于检测肝癌的生物标志物及其应用 | |
CN111228292B (zh) | 人tpt1/tctp基因在制备抗肿瘤药物中的应用 | |
CN116162624A (zh) | 一种高效敲除人PCL3基因sgRNA组合及其质粒、慢病毒、试剂盒和应用 | |
CN117357549A (zh) | 敲低METTL5基因的shRNA及其应用 | |
CN117187215A (zh) | 受化学小分子诱导重新组装的CRISPR/CasRx系统及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |